PAF (C16)

CAS No. 74389-68-7

PAF (C16)( —— )

Catalog No. M33743 CAS No. 74389-68-7

PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 105 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PAF (C16)
  • Note
    Research use only, not for human use.
  • Brief Description
    PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.
  • Description
    C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.
  • In Vitro
    C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR but not PAFR+/+ cultures. C16-PAF (1 μM) elicits neuronal death in PAFR cells infected with EGFP alone. C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR neurons.C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor.C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner.Cell Viability Assay Cell Line: Cerebellar granule neurons (CGNs) from PAFR?/? and PAFR+/+ mice Concentration:0.5-1.5 μM Incubation Time:24 hours Result:Elicited significant concentration-dependent neuronal loss in PAFR?/? but not PAFR+/+ cultures in serum-free media.Western Blot Analysis Cell Line:CGNs Concentration:1 μM Incubation Time:24 hours Result:Activated caspase 7 but not caspase 3 in PAFR?/? neurons.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    MAPK | MEK | Endogenous Metabolite | ERK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    74389-68-7
  • Formula Weight
    523.68
  • Molecular Formula
    C26H54NO7P
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (95.48 mM; Ultrasonic (<60°C); )H2O : 33.33 mg/mL (63.65 mM; Ultrasonic)
  • SMILES
    [C@H](COP(OCC[N+](C)(C)C)(=O)[O-])(COCCCCCCCCCCCCCCCC)OC(C)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Scott D Ryan, et al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8.?
molnova catalog
related products
  • Ginkgolide A

    Ginkgolide A is a highly active PAF antagonist cage molecule that is isolated from the leaves of the Ginkgo biloba tree. Shows potential in a wide variety of inflammatory and immunological disorders.

  • LY2228820 dimesylate

    LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor p38 MAPK with IC50 of 5.3 and 3.2 nM for p38α and p38β, respectively.

  • Nek2-IN-5

    Nek2-IN-5 (NCL00017509) is a potent and selective inhibitor of NIMA-related kinase 2 (Nek2).